Stock 4593 HEALIOS K.K.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Healios K.K.

Equities

4593

JP3835100003

Market Closed - Japan Exchange
Other stock markets
 07:00:00 10/05/2024 BST 		5-day change 1st Jan Change
155 JPY -2.52% Intraday chart for Healios K.K. +4.03% -6.06%
04-10 Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen MT
04-09 Healios K.K. Enters into Joint Research Agreement with AND Medical Group CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
HEALIOS K.K. Stock Healios K.K.
-6.06% 89.62M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
B+
ARGENX SE Stock argenx SE
+1.28% 22.25B
B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
B+
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4593 Stock
  4. Ratings Healios K.K.